Thomas A Fitzgerald Transcode Therapeutics, Inc. (RNAZ) insider trading activity

RNAZ Quotes by TradingView

Thomas A Fitzgerald is Interim CEO, CFO of Transcode Therapeutics, Inc.. Currently has a direct ownership of 56,318 shares of RNAZ, which is worth approximately $17,458. The most recent transaction as insider was on Sep 28, 2023, when has been sold 49,350 shares (Common Stock) at a price of $0.51 per share, resulting in proceeds of $25,168. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 56.3K
0% 3M change
59.59% 12M change
Total Value Held $17,458

Thomas A Fitzgerald Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 28 2023
BUY
Open market or private purchase
$25,168 $0.51 p/Share
49,350 Added 46.7%
56,318 Common Stock
Jun 16 2022
BUY
Open market or private purchase
$15,240 $1.27 p/Share
12,000 Added 7.93%
139,377 Common Stock
TAF

Thomas A Fitzgerald

Interim CEO, CFO
Boston, MA

Track Institutional and Insider Activities on RNAZ

Follow Transcode Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RNAZ shares.

Notify only if

Insider Trading

Get notified when an Transcode Therapeutics, Inc. insider buys or sells RNAZ shares.

Notify only if

News

Receive news related to Transcode Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on RNAZ